We actively identify, evaluate and build new technology platforms through external collaborations and partnerships, commercialize key products in China with domestic pharmaceutical/biotech capabilities, and work with multinational pharmaceutical/biotech companies to accelerate overseas development and maximize the value of key products globally. If you want to share a partnership or technology opportunity with Transcenta, please contact firstname.lastname@example.org.
Global clinical collaboration with BMS to evaluate Osemitamab (TST001) in combination with Opdivo® for 1L GC/GEJ cancer
A Joint Venture with Alebund Pharmaceuticals to develop and commercialize TST004 in renal diseases in Greater China
Several research collaborations have been established with leading academic institutions worldwide, including the Dana-Farber Cancer Institute at Harvard Medical School, Peking University Cancer Hospital, Shanghai Pulmonary Hospital, Sun Yat-sen Hospital, Sun Yat-sen University and Shanghai Jiaotong University. The research collaborations cover Osemitamab (TST001), TST003 and TST005.
Co-development with Merck KGaA, leveraging our expertise in continuous bioprocessing technology A multi-year collaboration to develop automated continuous downstream and other key enabling technologies